Literature DB >> 22222723

Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one-time and annual follow-up screening in rural China.

Rong Li1, Adam K Lewkowitz, Fang-Hui Zhao, Qi Zhou, Shang-Ying Hu, Hui Qiu, Yan Zhang, Hong-Wei Jiang, Jin-Song Zhang, Ming Li, Shao-Min Tong, Qiao-Yu Zhang, You-Lin Qiao.   

Abstract

PURPOSE: Via a large population-based survey conducted in rural, southwestern China, we aim to evaluate the effect of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) on diagnosing cases of cervical cancer and of pre-cancerous lesions while exploring the mode of cervical prevention and control in low-resource settings in China.
METHODS: Women aged 30-59 years from Chongqing, China were recruited from 2006 to 2009. Participants underwent VIA/VILI, and, if positive, received colposcopy-directed or random biopsies. Women with negative VIA/VILI or biopsy-confirmed cervical intraepithelial neoplasia (CIN) 1 lesions diagnosed in the first round of screening were re-screened in the following year with the same procedure.
RESULTS: In total, 10,269 women received VIA/VILI. The average age of participants was 40.9 ± 7.6 years. Overall, 0.85% (87/10,269) of women were diagnosed via pathology-confirmed biopsy with CIN1, 0.25% (26/10,269) with CIN2, 0.27% (28/10,269) with CIN3, and 0.02% (2/10,269) with cervical cancer. Over half (57.7%) of CIN2 lesions, the majority of CIN3 lesions (89.3%), and all cancer cases (100%) were detected in the first round of screening.
CONCLUSION: In a rural, low-resource setting in China, one-time VIA/VILI screening detected more than a half of CIN2 cases, most CIN3 cases and all the cervical cancer cases. Detection rates of CIN2 lesions significantly increased with a 1-year follow-up VIA/VILI screen. Therefore, if multiple cervical cancer screenings are not feasible logistically or financially, a one-time VIA/VILI may be the most efficient strategy to detect cervical cancer and most CIN3 lesions in women in low-resource settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222723      PMCID: PMC5463538          DOI: 10.1007/s00404-011-2203-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  17 in total

1.  Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial.

Authors:  Rengaswamy Sankaranarayanan; Pulikkottil Okkuru Esmy; Rajamanickam Rajkumar; Richard Muwonge; Rajaraman Swaminathan; Sivanandam Shanthakumari; Jean-Marie Fayette; Jacob Cherian
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

2.  China's plans to curb cervical cancer.

Authors:  Chihua Wen
Journal:  Lancet Oncol       Date:  2005-03       Impact factor: 41.316

3.  Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania.

Authors:  Twalib Ngoma; Richard Muwonge; Julius Mwaiselage; Jesca Kawegere; Pendo Bukori; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2010-02-12       Impact factor: 3.561

Review 4.  Accuracy of visual inspection with acetic acid for cervical cancer screening.

Authors:  Catherine Sauvaget; Jean-Marie Fayette; Richard Muwonge; Ramani Wesley; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2011-01-22       Impact factor: 3.561

5.  Accuracy of visual inspection with acetic acid (VIA) for early detection of cervical dysplasia in Tehran, Iran.

Authors:  Zahra Eftekhar; Parvaneh Rahimi-Moghaddam; Fariba Yarandi; Ronak Brojerdi
Journal:  Asian Pac J Cancer Prev       Date:  2005 Jan-Mar

Review 6.  Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy.

Authors:  P D Blumenthal; M Lauterbach; J W Sellors; R Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2005-05       Impact factor: 3.561

7.  Comparison of Papanicolaou test with visual detection tests in screening for cervical cancer and developing the optimal strategy for low resource settings.

Authors:  Pakhee Aggarwal; Swaraj Batra; Gauri Gandhi; Vijay Zutshi
Journal:  Int J Gynecol Cancer       Date:  2010-07       Impact factor: 3.437

8.  Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

Authors:  J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

9.  [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].

Authors:  Long-yu Li; Zhi-qiang Qiao; Min-fang Zhang; Jian-ping Yang; Yan-ping Bao; Yun-ting An; Jun Lei; Nan-hua Xiong; Xiao-hong Yu; Xun Zhang; Qin-jing Pan; You-lin Qiao
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2007-10

10.  [Three-year follow-up results of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].

Authors:  Yong-Zhen Zhang; Jun-Fei Ma; Fang-Hui Zhao; Xi-E Xiang; Zhao-Hui Ma; Ying-Tao Shi; Shang-Ying Hu; You-Lin Qiao
Journal:  Chin J Cancer       Date:  2010-01
View more
  3 in total

1.  Redesigning primary care to tackle the global epidemic of noncommunicable disease.

Authors:  Margaret E Kruk; Gustavo Nigenda; Felicia M Knaul
Journal:  Am J Public Health       Date:  2015-01-20       Impact factor: 9.308

2.  Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort study.

Authors:  Kelias Phiri Msyamboza; Twambilire Phiri; Wesley Sichali; Willy Kwenda; Fanny Kachale
Journal:  BMC Public Health       Date:  2016-08-17       Impact factor: 3.295

3.  Evaluating the implementation of cervical cancer screening programs in low-resource settings globally: a systematized review.

Authors:  J Andrew Dykens; Jennifer S Smith; Margaret Demment; E Marshall; Tina Schuh; Karen Peters; Tracy Irwin; Scott McIntosh; Angela Sy; Timothy Dye
Journal:  Cancer Causes Control       Date:  2020-03-17       Impact factor: 2.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.